Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually). 11. In patients with DVT of the leg or PE and active cancer ( cancer-associated thrombosis ) and who (i) do not have a high bleeding risk, we recommend extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 1B), and (ii) have a high bleeding risk, we suggest extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 2B). Remarks: In all patients who receive extended anticoagulant therapy, the continuing use of treatment should be reassessed at periodic intervals (eg, annually). Aspirin for Extended Treatment of VTE Summary of the Evidence AT9 did not address if there was a role for aspirin, or antiplatelet therapy generally, in the treatment of VTE. Since then, two randomized trials have compared aspirin with placebo for the prevention of recurrent VTE in patients with a rst unprovoked proximal DVT or PE who have completed 3 to 18 months of anticoagulant These trials provide moderate-quality evidence that extended aspirin therapy reduces recurrent VTE by about one-third. In these trials, the bene ts of aspirin outweighed the increase in bleeding, which was not statistically signi cant (Table 13, e-Table 14). The two trials enrolled patients with a rst unprovoked VTE who did not have an increased risk of bleeding; patients for whom these guidelines have suggested extended anticoagulant therapy. 